Amelia Williams
Physician Assistant · Bellville, TXNPI 1215162268
Payments from drug & device makers
Across 214 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$740
- AbbVie$644
- Mylan Specialty L.p.$456
- Amgen$367
- Takeda Pharmaceuticals U.S.A., Inc.$227
- GSK$122
- plus $965 from 22 others
What the payments were for
- Food & beverage$3,507100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $740 |
| AbbVie | 45 | $644 |
| Mylan Specialty L.p. | 30 | $456 |
| Amgen | 24 | $367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $227 |
| GSK | 4 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $122 |
| Exact Sciences | 6 | $119 |
| Lilly USA, LLC | 6 | $105 |
| Novartis | 4 | $59 |
| Axsome Therapeutics, Inc. | 4 | $58 |
| Novo Nordisk | 4 | $52 |
| Corcept Therapeutics | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $38 |
| Bayer | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Dexcom, Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Sanofi | 1 | $20 |
| Merck | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$3,521 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $131,708 |
| JardianceEmpagliflozin | 150 | $112,041 |
| EliquisApixaban | 65 | $60,190 |
| FarxigaDapagliflozin Propanediol | 30 | $42,807 |
| RybelsusSemaglutide | 15 | $34,062 |
| OzempicSemaglutide | 32 | $32,194 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $25,192 |
| TrintellixVortioxetine Hydrobromide | 37 | $21,266 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $19,324 |
| VraylarCariprazine Hcl | 12 | $17,077 |
| GemtesaVibegron | 24 | $14,940 |
| TrulancePlecanatide | 24 | $14,086 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $13,988 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $13,697 |
| Repatha SureclickEvolocumab | 23 | $13,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $105 | $131,708122 claims |
| Novo NordiskRybelsus, Ozempic | $52 | $66,25647 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $740 | $58,39252 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $122 | $39,18051 claims |
| AbbVieVraylar, Synthroid | $644 | $22,11675 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $227 | $21,26637 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $14,94024 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $122 | $14,08624 claims |
| NovartisEntresto | $59 | $11,91814 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $11,04225 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $34 | $4,85613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Bellville
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.